AKT1 and type 2 diabetes mellitus: Here, we investigated the molecular mechanism of the use of ATMP for T2DM treatment, showing that ATMP could inhibit glycogenesis via PI3K/Akt/GSK3β signaling pathway, suppress glycogenolysis by inhibiting cAMP/PKA signaling and reduce gluconeogenesis through activating the AMPK signaling pathway.